门静脉注射OKT9-ADM偶联物治疗原发性肝癌

用经门静脉注射转铁蛋白受体单抗－阿霉素（ＯＫＴ９ＡＤＭ）偶联物导向化疗结合肝动脉栓塞治疗１５例不能切除的原发性肝癌患者（第一组），同期另外１０例患者行肝动脉栓塞＋门静脉ＡＤＭ化疗作对照（第二组）。结果显示：第一组门静脉血内阿霉素浓度明显高于外周血和第二组门静脉血内阿霉素浓度。彩色多普勒超声引导癌栓穿刺活检显示，经门静脉导向化疗后，第一组有２例门静脉癌栓出现坏死，临床观察提示：经门静脉注射ＯＫＴ９ＡＤＭ偶联物对不能切除的肝癌的治疗是有效的，尤其是对门静脉癌栓的治疗可能比门静脉ＡＤＭ化疗更有效，但其远期疗效需进一步随机对照研究来评价。

STUDY ON UNRESECTABLE HCC TREATED BY INTROPORTAL ADMINISTRATION OF OKT 9 ADM CONJUGATE IN COMBINATION WITH HAE

Fifteen patients(group one)with surgically proven unresectable HCC were treated by introportal injection of OKT 9 ADM conjugate in combination with HAE. For the sake of contrast, ADM were administrated intraportalvenously for another ten cases (group two). The results showed that the ADM concentration in the portal flow in group one was obviously higher than that in group two. Of two patients in group one tumor thrombus was found to be necrosis by the fine needle biopsies under color Doppler ultrasound guidance. Our observations suggested that introportal administration of OKT 9 ADM conjugate was safe and effective for unresectable HCC especially for treating tumor thrombi in the portal vein. The long term effect of this treatment has yet to be investigated by controlled studies.